Help move controllable precision oncology forward.
GenLumina is developing a light-activated intracellular payload platform for targeted oncology. Molecular targeting determines where the payload goes. Light provides an independent spatial switch controlling where cytotoxic activity is activated.
From platform evidence to partner-specific validation.
GenLumina has established the scientific foundation for its light-controlled payload approach. The next phase is focused on strengthening preclinical evidence and evaluating the payload with targeting molecules selected by pharmaceutical partners. The goal is not to lock the platform into one target, but to establish a repeatable partnering model.
Three doors you can open.
Introductions can be as valuable as capital. GenLumina is looking for pharmaceutical partners, mission-aligned financiers and experienced people who can help accelerate the next preclinical and commercial steps.
Introduce a pharma or biotech partner
Connect us with companies developing antibodies, peptides, ligands or other targeting technologies that may benefit from an independently controllable intracellular payload.
Connect mission-aligned capital
Introduce private financiers, family offices, foundations or specialist investors interested in funding the next preclinical evidence steps.
Open the right strategic door
Know an oncology decision-maker, translational expert, medtech company or industry connector who should understand the platform? An introduction can start the conversation.
Bring your targeting biology. Define the proof of concept together.
A pharma or biotech partner can select an antibody, peptide, ligand or other targeting molecule. GenLumina contributes its light-activated payload, conjugation know-how and validation approach. Scope, decision criteria, funding and commercial next steps are agreed for each programme.
Who in your network should know about GenLumina?
A focused conversation is enough to explore whether your network, expertise, capital or technology can help move the next step forward.